Last reviewed · How we verify

HRS-6209 in Combination with Fulvestrant

Jiangsu HengRui Medicine Co., Ltd. · Phase 1 active Small molecule

HRS-6209 in Combination with Fulvestrant is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic nameHRS-6209 in Combination with Fulvestrant
SponsorJiangsu HengRui Medicine Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HRS-6209 in Combination with Fulvestrant

What is HRS-6209 in Combination with Fulvestrant?

HRS-6209 in Combination with Fulvestrant is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..

Who makes HRS-6209 in Combination with Fulvestrant?

HRS-6209 in Combination with Fulvestrant is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What development phase is HRS-6209 in Combination with Fulvestrant in?

HRS-6209 in Combination with Fulvestrant is in Phase 1.

Related